RNXT · RenovoRx, Inc.

Summary

RenovoRx, Inc. entered into a Securities Purchase Agreement on March 17, 2026, for a private placement offering to 15 investors, closing on March 20, 2026, issuing 8,438,790 shares of common stock, pre-funded warrants for 2,200,000 shares, and milestone warrants for 5,319,392 shares for gross proceeds of approximately $10 million before fees. The offering relies on Section 4(a)(2) and Rule 506 of Regulation D exemptions from registration.

Key takeaways

• Entered Securities Purchase Agreement on March 17, 2026, closed March 20, 2026
• Sold 8,438,790 shares of Common Stock at $0.938 per share (Institutional Investors) or $1.0288 (Insiders)
• Issued Pre-Funded Warrants to purchase 2,200,000 shares, exercisable at $0.0001, non-expiring
• Issued Milestone Warrants to purchase 5,319,392 shares (50% coverage) at $1.751 (Institutional) or $1.9326 (Insiders), expiring March 30, 2029 or 30 days after $1.5M quarterly product sales revenue
• 15 investors: 5 Insiders (directors, officers, employees) and Institutional Investors
• Placement Agent Konik Capital Partners, LLC receives 5.5% commission plus up to $50,000 expenses